Machine-learning-based bibliometric analysis of pancreatic cancer research over the past 25 years

K Wang, I Herr - Frontiers in Oncology, 2022 - frontiersin.org
Machine learning and semantic analysis are computer-based methods to evaluate complex
relationships and predict future perspectives. We used these technologies to define recent …

GSK-3β in pancreatic cancer: Spotlight on 9-ING-41, its therapeutic potential and immune modulatory properties

R Park, AL Coveler, L Cavalcante, A Saeed - Biology, 2021 - mdpi.com
Simple Summary Glycogen synthase kinase-3 beta is a protein kinase implicated in the
promotion and development of various cancers, including pancreatic cancer. In cell culture …

A Novel HOXA10-Associated 5-Gene–Based Prognostic Signature for Stratification of Short-term Survivors of Pancreatic Ductal Adenocarcinoma

SG Kisling, P Atri, A Shah, JL Cox, S Sharma… - Clinical Cancer …, 2023 - AACR
Purpose: Despite the significant association of molecular subtypes with poor prognosis in
patients with pancreatic ductal adenocarcinoma (PDAC), few efforts have been made to …

Exosomes, microvesicles, and other extracellular vesicles—a Keystone Symposia report

J Cable, KW Witwer, RJ Coffey… - Annals of the New …, 2023 - Wiley Online Library
Extracellular vesicles (EVs) are small, lipid‐bilayer‐bound particles released by cells that
can contain important bioactive molecules, including lipids, RNAs, and proteins. Once …

A novel anti-galectin-9 immunotherapy limits the early progression of pancreatic neoplastic lesions in transgenic mice

A Quilbe, R Mustapha, B Duchêne, A Kumar… - Frontiers in …, 2023 - frontiersin.org
Background Pancreatic adenocarcinoma (PDAC) is a devastating disease with an urgent
need for therapeutic innovation. Immune checkpoint inhibition has shown promise in a …

Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives

L Pekarek, O Fraile-Martinez… - Oncology …, 2021 - spandidos-publications.com
Pancreatic cancer has a dire prognosis and will represent the second leading cause of
cancer death in the next 10 years. The multifactorial approach represents one of the main …

Partial response in non-resectable adenosquamous carcinoma of the pancreas with high tumour mutation burden treated with gemcitabine, nab-paclitaxel and …

RP de la Fuente, JW Doolin… - BMJ Case Reports …, 2023 - casereports.bmj.com
A previously healthy man in his 60s was diagnosed with a rare histological subtype of
pancreatic cancer, adenosquamous carcinoma. After somatic mutation profiling, it was found …

Real‐world implications of nonbiological factors with staging, clinical management, and prognostic prediction in pancreatic ductal adenocarcinoma

C Wang, H Chen, X Deng, W Xu, B Shen - Cancer Medicine, 2023 - Wiley Online Library
Abstract Background The American Joint Committee on Cancer (AJCC) tumor‐node‐
metastasis (TNM) staging system focuses on traditional biological factors (BFs). The present …

The association of the sequence of immunotherapy with the survival of unresectable pancreatic adenocarcinoma patients: A retrospective analysis of the National …

S Amin, MJ Baine, JL Meza, C Lin - Frontiers in Oncology, 2020 - frontiersin.org
Background: Immunotherapy has shown great success in various malignancies. However,
its efficacy in pancreatic ductal adenocarcinoma (PDAC) remains a challenge, and the lack …

Exploring the Therapeutic Opportunities of the Tumour Microenvironment in Treating Pancreatic Ductal Adenocarcinoma: A Literature Review

J Dhaliwal - Undergraduate Research in Natural and Clinical …, 2022 - urncst.com
Introduction: Pancreatic ductal adenocarcinoma (PDA) is an invasive cancer of the exocrine
pancreas with a 5-year survival rate (< 8%), highlighting the need for new therapies to …